2025-05-28-Jefferies-火箭制药公司（RCKT）_由于关键的Danon心脏病项目出现一些不确定性_给予持有评级_12页_597kb

Rocket Pharmaceuticals (RCKT) Equity Research Summary

Rating and Target

• Current Rating: Hold (Buy)
• Target Price: $2.50 (+7% from $2.33)
• Key Concern: FDA clinical hold on pivotal Phase II program of RP-A501 for Danon heart disease due to safety issues, including patient death from capillary leak syndrome.

Program Updates

• RP-A501 (Danon Disease): Delays in pivotal Phase II data and safety profile raise uncertainty. Company is working with FDA, DMC, and experts to address root cause; no additional deaths reported since hold. Peak sales revised to $500M vs. previous $1B+ estimate.
• Other Programs: RP-L201 and RP-L102 in regulatory phases for LAD-I and Fanconi anemia, potentially approved in 2026. No impact on RP-A501 program at this time.

Financial Position

• Cash Runway: Q1 2025 cash is $318M, with potential delays due to clinical hold. Approval of priority review vouchers (PRVs) for LAD-I/FA programs could provide non-dilutive capital.
• Expenses: High R&D costs in 2024 ($24M); resource reallocation could mitigate cash burn.
• Projections: Financial statements show losses, with a DCF-based valuation. Cash is critical to extend operations until pivotal data or PRV approval.

Risks and Timeline Uncertainties

• Safety Questions: Isolated event risk for capillary leak syndrome unresolved; may delay patient enrollment.
• Regulatory Path: Timeline for FDA hold lifting and data generation unclear. Potentially pushed-back catalysts include Danon webinar update and regulatory submissions.
• Market Dynamics: Overall benefit-risk profile weakens due to safety SAE, reducing peak sales estimates.

Investment Thesis

• Hold Rating Basis: Downgrade from Buy due to uncertainties at RP-A501.Rating may revert to Buy only if: safety risks are manageable (e.g., preventable TMA), FDA hold lifted with no further issues, or efficacy data support higher sales estimates. Financials and timing remain key constraints.

Key Catalysts

• Upside: FDA approval of RP-L201/RP-L102, successful RP-A501 data by YE:25, securing PRVs.
• Downside: Delayed timelines, cash depletion, unresolved safety concerns.